Using cognitive computing to identify compounds with antidyskinetic potential for Parkinson’s disease
Objective: IBM Watson for Drug Discovery (WDD) is a platform that analyzes vast quantities of scientific data to help researchers identify hidden connections and formulate…Levodopa/carbidopa Intestinal Gel Can Improve Both Motor and Non-Motor Experiences of Daily Living in Parkinson’s Disease: An Open-Label Study
Objective: : Our aim was to determine if the MDS-UPDRS and UDysRS could detect improvement in the experiences of daily living following 1-year LCIG treatment.…Dynamic stability during turning in people with Parkinson’s disease
Objective: The goal of this study is to determine the contributions of dyskinesia to abnormal turning mechanisms. Background: The ability to turn safely while…Mechanisms of sub-anesthetic ketamine infusions to reduce L-DOPA-induced dyskinesia: effects on striatal mTOR signaling and beta band oscillations in striatum and motor cortex
Objective: To evaluate mechanism of long-term activity of sub-anesthetic ketamine infusion to reduce L-DOPA-induced dyskinesia (LID). Background: We have published preclinical evidence and patient case…Serotonin–to–dopamine transporter ratios in Parkinson’s dyskinesias: the longitudinal study
Objective: This study was designed to detect whether in Parkinson’s disease (PD) the putaminal serotonin–over–dopamine transporter ratio has a threshold that is critical for the…Reliability of Continuous Parkinson’s Assessment Using Wearables
Objective: To evaluate test-retest reliability and determine the optimal number of days of use for wearable sensors and a mobile software app to continuously and…The clinically-available anti-depressant mirtazapine alleviates both psychosis and dyskinesia in the MPTP-lesioned marmoset
Objective: To determine the effect of mirtazapine, a clinically-available anti-depressant, on psychosis and dyskinesia in Parkinson’s disease (PD). Background: Psychosis and dyskinesia cause significant morbidity…SPECT imaging of striatal DAT availability in Parkinson’s: changes over time and relevance to dyskinesias
Objective: This study was designed to explore in Parkinson’s disease (PD) the role of dopamine transporter (DAT)-specific single photon emission computed tomography (SPECT) imaging as a…Wearable motion quantification and electronic diaries for long-term monitoring of Parkinson’s disease
Objective: To clinically assess wearable motion sensors for measuring tremor, dyskinesia, slowness, and mobility and an electronic diary for Parkinson’s disease (PD) Background: A patient…The highly-selective mGluR2 positive allosteric modulator LY-487,379 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effectiveness of highly-selective metabotropic glutamate 2 receptor (mGluR2) activation at alleviating and preventing the development of L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. Background: Chronic…
- « Previous Page
- 1
- …
- 34
- 35
- 36
- 37
- 38
- …
- 44
- Next Page »